ArticleBioinformation2025
Effect of autologous platelet concentrates on osteoblast cell activity during early osseointegration.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in implant dentistry focuses on enhancing the predictability of implant success using advanced regenerative techniques. Autologous platelet concentrates rich in growth factors play a crucial role in stimulating osteoblast activity and improving osseointegration at implant sites. Therefore, it is of interest to evaluate the osteogenic efficacy of four injectable platelet concentrates: (1) injectable-platelet-rich fibrin, (2) leukocyte platelet-rich fibrin, (3) advanced platelet-rich fibrin and (4) Advanced platelet-rich fibrin + on titanium surfaces. All tested concentrates enhanced osteoblastic adhesion, differentiation and mineralization, with injectable-platelet-rich fibrin demonstrating the most significant calcium nodule formation. Thus, injectable-platelet-rich fibrin proved to be the most effective in promoting early osseointegration compared to the other platelet-rich fibrin types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.